STE Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies has a net margin of 9.84% compared to Steris PLC's net margin of -163.76%. Steris PLC's return on equity of 9.5% beat NeuroOne Medical Technologies's return on equity of -281.01%.

Steris PLC has a consensus price target of $264.88, signalling upside risk potential of 16.37%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of $1.45 which suggests that it could grow by 100.42%. Given that NeuroOne Medical Technologies has higher upside potential than Steris PLC, analysts believe NeuroOne Medical Technologies is more attractive than Steris PLC.

Steris PLC has a beta of 0.923, which suggesting that the stock is 7.704% less volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.052%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Steris PLC pays 35.77% of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.5B, which are larger than NeuroOne Medical Technologies quarterly revenues of $1.4M. Steris PLC's net income of $145.7M is higher than NeuroOne Medical Technologies's net income of -$2.3M. Notably, Steris PLC's price-to-earnings ratio is 36.71x while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.13x versus 3.74x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of 9.84% compared to Steris PLC's net margin of -208.09%. Steris PLC's return on equity of 9.5% beat Nutriband's return on equity of -102.63%.

Steris PLC has a consensus price target of $264.88, signalling upside risk potential of 16.37%. On the other hand Nutriband has an analysts' consensus of $15.00 which suggests that it could grow by 84.73%. Given that Nutriband has higher upside potential than Steris PLC, analysts believe Nutriband is more attractive than Steris PLC.

Steris PLC has a beta of 0.923, which suggesting that the stock is 7.704% less volatile than S&P 500. In comparison Nutriband has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.565%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Steris PLC pays 35.77% of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.5B, which are larger than Nutriband quarterly revenues of $667.4K. Steris PLC's net income of $145.7M is higher than Nutriband's net income of -$1.4M. Notably, Steris PLC's price-to-earnings ratio is 36.71x while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.13x versus 37.58x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of 9.84% compared to Steris PLC's net margin of -787.63%. Steris PLC's return on equity of 9.5% beat SINTX Technologies's return on equity of -180.99%.

Steris PLC has a consensus price target of $264.88, signalling upside risk potential of 16.37%. On the other hand SINTX Technologies has an analysts' consensus of $28.00 which suggests that it could grow by 910.83%. Given that SINTX Technologies has higher upside potential than Steris PLC, analysts believe SINTX Technologies is more attractive than Steris PLC.

Steris PLC has a beta of 0.923, which suggesting that the stock is 7.704% less volatile than S&P 500. In comparison SINTX Technologies has a beta of 0.713, suggesting its less volatile than the S&P 500 by 28.749%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Steris PLC pays 35.77% of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.5B, which are larger than SINTX Technologies quarterly revenues of $291K. Steris PLC's net income of $145.7M is higher than SINTX Technologies's net income of -$2.3M. Notably, Steris PLC's price-to-earnings ratio is 36.71x while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.13x versus 2.66x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of 9.84% compared to Steris PLC's net margin of 9.53%. Steris PLC's return on equity of 9.5% beat Zimmer Biomet Holdings's return on equity of 7.29%.

Steris PLC has a consensus price target of $264.88, signalling upside risk potential of 16.37%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $108.44 which suggests that it could grow by 15.09%. Given that Steris PLC has higher upside potential than Zimmer Biomet Holdings, analysts believe Steris PLC is more attractive than Zimmer Biomet Holdings.

Steris PLC has a beta of 0.923, which suggesting that the stock is 7.704% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.957%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1%. Zimmer Biomet Holdings offers a yield of 1.02% to investors and pays a quarterly dividend of $0.24 per share. Steris PLC pays 35.77% of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.5B, which are smaller than Zimmer Biomet Holdings quarterly revenues of $1.9B. Steris PLC's net income of $145.7M is lower than Zimmer Biomet Holdings's net income of $182M. Notably, Steris PLC's price-to-earnings ratio is 36.71x while Zimmer Biomet Holdings's PE ratio is 20.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.13x versus 2.48x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.